Clinical Trial Update: Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir [Phase 3]

View source ↗

Summary

A phase 3 multicenter, randomized trial comparing elvitegravir to raltegravir for HIV infection has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)
• Vitekta (elvitegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV Infection | Phase 3 | Status: COMPLETED | Results posted: 2014-11-06